Jounce Therapeutics Inc (NASDAQ:JNCE) Given Average Rating of “Hold” by Analysts

Share on StockTwits

Jounce Therapeutics Inc (NASDAQ:JNCE) has been assigned an average recommendation of “Hold” from the six ratings firms that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $9.00.

JNCE has been the topic of a number of research reports. Cowen reissued a “hold” rating on shares of Jounce Therapeutics in a report on Tuesday, November 12th. ValuEngine lowered Jounce Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, December 17th. Zacks Investment Research raised Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 price objective on the stock in a report on Saturday. BidaskClub lowered Jounce Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 7th. Finally, TheStreet raised Jounce Therapeutics from a “d” rating to a “c-” rating in a report on Wednesday, December 11th.

In other Jounce Therapeutics news, CEO Richard /Ca/ Murray sold 7,150 shares of Jounce Therapeutics stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $7.78, for a total value of $55,627.00. Following the sale, the chief executive officer now owns 87,360 shares of the company’s stock, valued at approximately $679,660.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 11,274 shares of company stock worth $88,207 in the last ninety days. 44.41% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. lifted its position in shares of Jounce Therapeutics by 1.8% during the 2nd quarter. BlackRock Inc. now owns 1,163,750 shares of the company’s stock valued at $5,760,000 after acquiring an additional 20,646 shares during the period. Vanguard Group Inc. lifted its position in shares of Jounce Therapeutics by 30.8% during the 2nd quarter. Vanguard Group Inc. now owns 800,150 shares of the company’s stock valued at $3,961,000 after acquiring an additional 188,540 shares during the period. State Street Corp lifted its position in shares of Jounce Therapeutics by 12.5% during the 3rd quarter. State Street Corp now owns 420,677 shares of the company’s stock valued at $1,401,000 after acquiring an additional 46,608 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Jounce Therapeutics by 5.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 295,568 shares of the company’s stock valued at $1,384,000 after acquiring an additional 15,125 shares during the period. Finally, Prudential Financial Inc. lifted its position in shares of Jounce Therapeutics by 20.2% during the 2nd quarter. Prudential Financial Inc. now owns 250,234 shares of the company’s stock valued at $1,239,000 after acquiring an additional 42,011 shares during the period. 70.58% of the stock is currently owned by institutional investors.

Shares of NASDAQ JNCE traded up $0.36 during midday trading on Tuesday, reaching $7.44. 758,949 shares of the company were exchanged, compared to its average volume of 648,328. The company has a current ratio of 13.60, a quick ratio of 13.60 and a debt-to-equity ratio of 0.09. Jounce Therapeutics has a 1 year low of $2.79 and a 1 year high of $10.00. The stock has a fifty day simple moving average of $7.80 and a 200 day simple moving average of $4.95. The stock has a market cap of $235.27 million, a P/E ratio of -8.86 and a beta of 3.98.

Jounce Therapeutics (NASDAQ:JNCE) last released its quarterly earnings results on Thursday, November 7th. The company reported $2.90 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.24 by $0.66. Jounce Therapeutics had a return on equity of 64.54% and a net margin of 46.11%. The firm had revenue of $119.45 million for the quarter, compared to analyst estimates of $99.97 million. As a group, analysts forecast that Jounce Therapeutics will post 1.92 earnings per share for the current year.

About Jounce Therapeutics

Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.

Further Reading: Dividend Achievers

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.